Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06545292 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients

Study acronym: MSTDM
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 31, 2026 to Dec 31, 2027 · Study sites: 0 to 1 · Completion date: Jul 1, 2027 to Jul 1, 2028 · 3 morev3 Show 6 more changesShow less
    • Primary completion date: Dec 31, 2026 to Dec 31, 2027
    • Study sites: 0 to 1
    • Completion date: Jul 1, 2027 to Jul 1, 2028
    • Start date changed from estimate of Oct 1, 2025 to Oct 6, 2025
    • Eligibility criteria expanded, about 6 words
    • Study description expanded, about 15 words

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: Sep 1, 2024 to Oct 1, 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study is to perform a clinical validation of the analytical method for dried blood spot microsampling of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutamide, nivolumab, ipilimumab, pembrolizumab, atezolizumab, bevacizumab or enfortumab vedotin. The secondary objective is to test the feasibility of home monitoring (microsampling TDM) of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutamide, nivolumab, ipilimumab, pembrolizumab, atezolizumab, bevacizumab or enfortumab vedotin in oncology patients.
Trial Details
NCT Number NCT06545292
Lead Sponsor Leiden University Medical Center
Conditions Drug Monitoring
Enrollment 360 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov